



563584-  
CLM202694

### Agreement summary sheet

|   |  |                            |           |
|---|--|----------------------------|-----------|
| External Party name:  | Medicinsk Hepato-gastroenterologisk Afdeling V, Aarhus University Hospital, Professor Hendrik Vilstrup   |                            |           |
| Description of goods or services to be provided by the supplier       | Pfizer will sponsor a meeting arranged by Dept. V, AUH.  |                            |           |
| Payment terms (Days)  |  |                            |           |
| 1. Effective date<br>2. Expiration date<br>3. Termination clauses     | 1.<br>17. Nov. 2015  | 2.<br>17. Nov. 2015<br>30' | 3.<br>N/A |
| Agreement administrator:  | Lone Gamrath   |                            |           |
| Contract manager:   | Lone Gamrath   |                            |           |
| ACM No. (If applicable)   | WS2698756  |                            |           |
| Business Unit / Department:   | OBU  |                            |           |
| Confidentiality clauses/data privacy                                  | Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Yes = Only a few people can view the Contract – restricted access  |                            |           |
| <b>CP#102 Checklist</b><br>Is this an Enhanced Control Due Diligence? | Yes <input type="checkbox"/> No <input checked="" type="checkbox"/><br>If yes, fill in the <a href="#">Contract Due Diligence Checklist</a>  |                            |           |
| FCPA-connection:  | <p><b>The agreement is</b></p> <p>A <input checked="" type="checkbox"/> Consultancy or other kind of service agreement with HCP/GO<br/> <input type="checkbox"/> Substantial consultancy agreement<br/> <input checked="" type="checkbox"/> "Ordinary" consultancy agreement</p> <hr/> <p>B <input type="checkbox"/> <b>3rd party agreement</b><br/> <input type="checkbox"/> is review transactions and requires a DDQ<br/> <input type="checkbox"/> is not a review transaction.</p> <p><b>3rd party is VIGO</b><br/> <input type="checkbox"/> Yes (please review and complete the FCPA requirements for VIGOs)<br/> <input type="checkbox"/> No</p> |                            |           |



Medicinsk Hepato-Gastroenterologisk Afdeling V  
 Aarhus Universitetshospital  
 Nørrebrogade 44  
 8000 Aarhus C  
 Att.: Lærestolsprofessor, overlæge, dr.med Hendrik Vilstrup

MODTAGET  
 09 NOV. 2015

Ballerup, 23. oktober 2015

**Agreement on support to: Regional meeting (Region Midt) 17. November 2015**

**Parties**

Pfizer ApS (hereafter referred to as Pfizer) wishes to provide support to The Hepato-gastroenterology regional meeting for specialists from Region Midt on the 17<sup>th</sup> of November 2015, and has therefore entered into this Agreement with Medicinsk Hepato-Gastroenterologisk afdeling V, Aarhus Universitetshospital (hereafter referred to as the Organization).

**Scope and purpose of the Agreement**

The purpose of this agreement shall be to support the meeting with a maximum of 24.500,00 DKK (700 DKK x 35 participants, if less participants the support will be 700 DKK x actual number of participants)

The support Pfizer will provide is given under the condition that it is used to cover expenses in connection with academic and scientific activities including appropriate amount of food and beverages. It may not be used to sponsor or organize activities of a solely social or cultural character or any other non-academic activities.

**Roles of the parties in the project**

Pfizer undertakes during the terms of this Agreement to support the meeting financially. The Organization shall undertake to arrange and conduct the meeting.

Any promotional activity/display must be separated from all academic and scientific activities and in addition it must be separated from the general public.

Please be aware that according to ENLI rules no gifts must be provided to healthcare professionals, unless they fall into a category of items that are otherwise permitted under the ENLI code. This prohibition applies for all activities sponsored or co-sponsored by a pharmaceutical company.

**Timeframe**

The agreement shall run on 17<sup>th</sup>. November 2015

**Financial support**

Pfizer's financial commitment in relation to this Agreement shall be with a maximum of 24.500,00 DKK (700 DKK x 35 participants, if less participants the support will be 700 DKK x actual number of participants) DKK excl. VAT.

**Non-financial support**

Pfizer will not provide any non-financial support.

**Report of activity to ENLI**

The sponsorship is reported to ENLI (The Ethical Committee for the Pharmaceutical Industry), prior to the activity and by Pfizer's opinion it is in compliance with all applicable rules although the arrangement has not been pre-approved by ENLI.

**Documentation**

Upon Pfizer's request, the Organization shall provide documentation that the support is spend in accordance with the Agreement and that the combined support does not exceed the actual expenses. Any surplus from the sponsorship not used for activities of a professional medical nature should be refunded.

**Data Privacy**

Information regarding name and contact information in relation to this agreement will be stored in a Pfizer global electronic system. You should be aware that some of the members of Pfizer group, legal counsel and/or regulatory authorities could have access to information as described above are located in countries whose laws protecting personal information may not be equivalent to those in your country. In particular, personal data disclosed to Pfizer Inc. by members of the Pfizer group within the European Economic Area and Switzerland are protected by Pfizer Inc.'s participation in the "safe harbour" schemes administered by the U.S. Department of Commerce.

You have right to access or, where incorrect, amend information pertaining to you that is in Pfizer's possession.

---

By signing this Agreement you confirm to have read and understood Pfizer's Representations and Warranties pursuant to Appendix A ("Representations and Warranties") and that the support is spend in accordance with the above mentioned terms and conditions.

Date: 4.11.2015

Signature of authorized signatory on behalf of Pfizer ApS:



Name: Lone Gamrath  
Title: Commercial Strategy Manager

Date:

Signature of authorized signatory on behalf of Medicinsk Hepato-Gastroenterologisk Afdeling V Aarhus Universitetshospital



Lærestolsprofessor, overlæge, dr.med Hendrik Vilstrup

## **Appendix A - Representations and Warranties**

- 1.1 The financial support from Pfizer will not cause your entity and, to your knowledge, any individuals affiliated with your entity or this support, to do anything that would result in Pfizer improperly obtaining or retaining business or gaining any improper business advantage;
- 1.2 Neither your entity nor, to your knowledge, any individuals affiliated with your entity or this support, will use any portion of the financial support from Pfizer to directly or indirectly offer or pay any money or anything of value in an effort to influence any Government Official or any other person in order for Pfizer to improperly obtain or retain business or to gain an improper business advantage, and, have not accepted, and will not accept in the future, such a payment;
- 1.3 If the support is an educational grant or otherwise to support an educational program, your entity agrees to disclose the fact that Pfizer is providing financial support for the educational program;
- 1.4 Pfizer may at any time publicly disclose that it has provided you with financial support, including the amount of such support; and
- 1.5 Pfizer will be entitled to revoke or suspend any financial support if Pfizer learns that your entity or any individuals affiliated with your entity or this support has used or intends to use any portion of the support to improperly seek to influence any Government Official or any other person in order to obtain or retain business or gain a business advantage.